Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652642 | 0.83 | MAPK14 (0.56) | MAPK14MAPK11CSNK1DMAPK13MAPK12 | |
| SCHEMBL2931805 | 0.80 | MAPK14 (0.47) | MAPK14MAPK11CSNK1DMAPK13MAPK12 | |
| SCHEMBL1384759 | 0.75 | CSNK1D (0.51) | MAPK14MAPK11CSNK1DMAPK13MAPK12 | |
| SCHEMBL1386407 | 0.74 | MAPK14 (0.52) | MAPK14MAPK11CSNK1DMAPK13MAPK12 | |
| SCHEMBL4932513 | 0.71 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12IDO1 | |
| SCHEMBL7492228 | 0.68 | MAPK14 (0.48) | MAPK14MAPK11MAPK13MAPK12IDO1 | |
| SCHEMBL7495308 | 0.67 | MAPK14 (0.45) | MAPK14MAPK11MAPK13MAPK12TGFBR1 | |
| SCHEMBL15638845 | 0.67 | TGFBR1 (0.57) | MAPK14MAPK11CSNK1DTGFBR1CSNK1E | |
| SCHEMBL2326694 | 0.66 | ADORA2A (0.75) | MAPK14MAPK11MAPK13MAPK12ADORA2A | |
| SCHEMBL30224316 | 0.66 | KMO (0.42) | MAPK14MAPK11MAPK13MAPK12IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | claimed |
| JP-4814783-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | claimed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| EP-1611131-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach y Compagnia S.A. (ES) | 2006-01-04 | — | — | EP | claimed |
| WO-2004076450-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach Y Compañia S.A. (ES) | 2004-09-10 | — | — | WO | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | MAPK14 34/4885MAPK11 40/4885CSNK1D 75/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885MAPK11 40/4885CSNK1D 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.